OPTIMIZED FIBERS FOR THE INTRAVENOUS MEMBRANE OXYGENATOR

Information

  • Research Project
  • 6142595
  • ApplicationId
    6142595
  • Core Project Number
    R43HL065118
  • Full Project Number
    1R43HL065118-01
  • Serial Number
    65118
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2000 - 24 years ago
  • Project End Date
    11/30/2001 - 23 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/2000 - 24 years ago
  • Budget End Date
    11/30/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/14/2000 - 24 years ago
Organizations

OPTIMIZED FIBERS FOR THE INTRAVENOUS MEMBRANE OXYGENATOR

The goal of this program is to develop hollow-fiber membranes and fiber fabrics that are customized for use in the Intravenous Membrane Oxygenator (IMO) under development at the University of Pittsburgh. The IMO is being developed as a method of augmenting incomplete respiration in adults with acute respiratory failure. Although the current versions of the IMO perform adequately, the gas-exchange rate of the IMO is not optimal. Specifically, the commercially available hollow-fiber membranes and fiber fabrics used in the IMO do not result in maximum membrane area in the device, limiting gas exchange. The goal of this program is to develop hollow-fiber membranes and fabrics specifically designed to optimize gas exchange in the IMO. In Phase I, we propose to develop hollow-fiber membranes with the optimum dimensions, strength, and permeability. We will work with researchers at the University of Pittsburgh to evaluate these fibers in a prototype IMO. Success in Phase I would lead to a Phase II program focused on optimization of the hollow-fiber membranes and fiber fabrics made from these membranes. Phase II would culminate with long-term tests of the prototype devices in animals at the University of Pittsburgh, demonstrating the effectiveness of the technology. PROPOSED COMMERCIAL APPLICATIONS: Development of the improved hollow-fiber membranes should make possible the practical application of the IMO. The membranes also promise to be useful for other commercial products, including extracorporeal oxygenators.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    838
  • Ed Inst. Type
  • Funding ICs
    NHLBI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BEND RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    977018583
  • Organization District
    UNITED STATES